ANO1 and asthma: Studies suggest that the increase in TMEM16A activity is related to the pathogenesis of asthma, so that the inhibition of this protein characterizes a therapeutic alternative for this disease, especially related to the control of mucus hypersecretion, a potentially serious characteristic that culminates in airway obstruction.